SCHEMBL1806019

SCHEMBL1806019

Cc1n[nH]c(-c2ncccc2CN(C)C)c1C=O

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.36
EDNRA P25101 1/20 0.31
ERN1 O75460 1/20 0.31
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
SLC6A3 Q01959 1/20 0.30
CYP1A2 P05177 2/20 0.30
CYP3A4 P08684 2/20 0.30
CYP2C8 P10632 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
CYP2D6 P10635 1/20 0.30
HPGD P15428 1/20 0.30
TSHR P16473 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1807044 0.82 CYP1A2 (0.36) ERN1CYP1A2CYP3A4CYP2C8CYP2C9
SCHEMBL1842089 0.81 CYP1A2 (0.37) CYP1A2CYP3A4CYP2C9CYP2C19KDM4E
SCHEMBL1806341 0.79 TRPV1 (0.37) TRPV1SLC6A4CYP1A2CYP3A4KDM4E
SCHEMBL1808007 0.78 KDM4E (0.34) CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL1803650 0.78 MEN1 (0.37) TRPV1ERN1KDM4EALDH1A1
SCHEMBL1807207 0.78 ERN1 (0.34) TRPV1ERN1
SCHEMBL1809432 0.78 ALDH1A1 (0.33) EDNRASLC6A2SLC6A4KDM4EALDH1A1
SCHEMBL1810225 0.77 P2RX7 (0.36) EDNRASLC6A2SLC6A4SLC6A3CYP3A4
SCHEMBL1805935 0.75 PDE4D (0.46) TRPV1KDM4EALDH1A1HPGDTSHR
SCHEMBL1805952 0.73 DRD1 (0.39) ERN1SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2501703-A1 SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS Eli Lilly and Company (US) 2012-09-26 EP disclosed
WO-2011060035-A1 SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2011-05-19 WO disclosed